sector medic suppli devic
messag full result came even better alreadi impress
pre-announce sale rose yoy perform cap year
compani handili beat street expect biggest
question view trajectori busi guidanc call sharp
slowdown sale cc vs feel conserv even
factor like price headwind yet visibl sever key variabl limit
continu view high expect potenti obstacl stock
cap remark style total revenu rose
yoy beat consensu compani busi maintain
impress momentum quarter sale top street expect
mark compani fifth consecut quarter strong gain domest
 growth acceler level saw continu
work toward shift sale channel dme pathway pharmaci
cover live access conveni pharmaci channel
improv patient access come price howev manag estim
reduc revenu per patient headwind like lower
sale thu far price headwind off-set ramp
volum manag provid color current instal base
estim new patient add nearli doubl vs question move
whether rapid pace adopt continu
part manag reiter guidanc revenu
impli growth ex-fx would repres sharp deceler
cc growth post adjust expect price headwind
cite outlook impli closer gain believ deceler
like comp get tougher rapid influx new cgm patient saw across
entir market moder outlook still strike us somewhat conserv
particular ramp new patient add past quarter provid continu
momentum model suggest instal base
like bigger today time last year incom statement
manag guid less oper leverag deliv past two
year gross margin forecast slightli yoy vs sg save
harder come compani invest addit support resourc servic
rapidli grow custom base model call post adjust
ep total revenu cc
turn back quarter intern busi came shi street
expect ou revenu miss consensu still grew
impress cc product level basi global sensor sale
came consensu drove major beat hardwar sale
also surpris upsid transmitt receiv
top street expect respect go forward
expect transmitt growth continu lag behind sensor promot broader
access hardwar rebat pharmaci channel long-term transit
featur integr sensor/transmitt fulli dispos increas
use mobil app rather dedic receiv like put addit pressur
hardwar compon busi
top-lin strong opex manag off-set gm pressur allow
revenu upsid fall earn report gross margin
yoy consensu elsewher sg expens rose
yoy sale street estim meanwhil spend
increas yoy revenu consensu combin drove
adjust ep vs street estim
page analyst certif import disclosur
pipelin front shape somewhat unev year
compani expect introduc lower cost transmitt
help off-set pressur margin reduc revenu per patient
product enhanc beyond may wait next year howev
manag noncommit potenti time extend sensor life
still track toward late earli fda approv clinic front
slate kick trial later year studi impact cgm in-hospit
glucos manag gestat diabet compani also continu collabor
onduo pilot program non-intens type popul outsid
pipelin pump partner remain track fda approv control-
enter strong momentum believ alreadi larg
reflect stock base revis estim share trade
ntm revenu level commensur top-lin growth outlook compani
strong perform give us increment confid deliv kind growth
long-term howev remain concern potenti price
continu meaning headwind even current channel shift play
come year busi deliv sizabl beat vs sell-sid
consensu manag guidanc worri high investor expect could
repres obstacl share appreci near-term result maintain
neutral rate
page analyst certif import disclosur
san diego ca base medic devic compani focus develop
continu glucos monitor cgm technolog aid treatment
manag diabet compani launch first cgm system st
follow recent fda approv new system sixth gener
cgm technolog last twelv year time led way
cgm grown world-wide market posit impact live
believ continu glucos monitor cgm way becom standard
care insulin-depend diabet nearli year sinc introduct
countless studi valid advantag cgm tradit point in-tim
blood glucos test reduc critic factor manag diabet
yet despit compel clinic evid support use estim penetr
remain rel low today approxim type popul less
insulin-intens type patient mani factor contribut
lacklust adopt view includ inconsist sensor accuraci conveni
qualiti life issu high increment cost therapi recent advanc
address mani histor drawback technolog pave way
bullish outlook cgm adopt abil sustain
leadership posit market time believ field enter disrupt
phase spur rapid influx new technolog feedback recent physician
patient survey suggest us could risk share
price perspect dynam current take back seat posit market
fundament still see long-term risk given share
current trade see limit upsid potenti prefer wait better entri
valu primarili ev/sal basi use repres group small-
to-mid cap med-tech name similar growth characterist comp base
guggenheim factset consensu estim current trade ntm
sale premium rang comp group see valuat
fair thu assign share neutral rate
upsid risk rate includ cgm penetr ramp faster expect
product pipelin could improv competit popul open
opportun potenti adopt competit cgm technolog could
fall short street expect
downsid risk rate includ greater expect adopt competit
cgm technolog price pressur reduc sale margin failur
continu solidli execut oper
page analyst certif import disclosur
million usd except
good sold
compani report guggenheim secur llc estim
page analyst certif import disclosur
million usd
revenu compon
compani report guggenheim secur llc estim
page analyst certif import disclosur
